Via Mavupharma takeout, AbbVie gets first-in-class STING target

The acquisition of Mavupharma gives AbbVie a first-in-class indirect STING booster close to the clinic that inhibits a target unexploited by other companies in oncology.

James Topper of Frazier Healthcare Partners, which led three-year-old Mavupharma Inc.’s $20 million series A round in late 2017, told

Read the full 443 word article

User Sign In